- Home
- REVG vs BLTE Comparison
REVG vs BLTE Comparison
Compare REVG & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVG
- BLTE
- Stock Information
- Founded
- REVG 2008
- BLTE 2018
- Country
- REVG United States
- BLTE United States
- Employees
- REVG N/A
- BLTE N/A
- Industry
- REVG Auto Manufacturing
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- REVG Consumer Discretionary
- BLTE Health Care
- Exchange
- REVG Nasdaq
- BLTE Nasdaq
- Market Cap
- REVG 2.9B
- BLTE 2.6B
- IPO Year
- REVG 2017
- BLTE 2022
- Fundamental
- Price
- REVG $61.11
- BLTE $93.49
- Analyst Decision
- REVG Hold
- BLTE Strong Buy
- Analyst Count
- REVG 4
- BLTE 4
- Target Price
- REVG $53.00
- BLTE $96.00
- AVG Volume (30 Days)
- REVG 576.8K
- BLTE 69.4K
- Earning Date
- REVG 12-10-2025
- BLTE 11-11-2025
- Dividend Yield
- REVG 0.39%
- BLTE N/A
- EPS Growth
- REVG N/A
- BLTE N/A
- EPS
- REVG 2.12
- BLTE N/A
- Revenue
- REVG $2,397,000,000.00
- BLTE N/A
- Revenue This Year
- REVG $4.82
- BLTE N/A
- Revenue Next Year
- REVG $8.06
- BLTE N/A
- P/E Ratio
- REVG $29.04
- BLTE N/A
- Revenue Growth
- REVG N/A
- BLTE N/A
- 52 Week Low
- REVG $25.76
- BLTE $49.00
- 52 Week High
- REVG $64.47
- BLTE $94.00
- Technical
- Relative Strength Index (RSI)
- REVG 65.00
- BLTE 76.29
- Support Level
- REVG $57.91
- BLTE $88.00
- Resistance Level
- REVG $61.97
- BLTE $94.00
- Average True Range (ATR)
- REVG 1.51
- BLTE 2.91
- MACD
- REVG 0.45
- BLTE 0.75
- Stochastic Oscillator
- REVG 88.58
- BLTE 96.98
About REVG REV Group Inc.
REV Group Inc is a United States-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services. During the first fiscal quarter of 2024, the Company formed the Specialty Vehicles Segment by combining the Fire & Emergency and Commercial segment businesses. Additionally, the Recreation segment was renamed Recreational Vehicles. As a result, the Company is now organized into two reportable segments. The company operates in the United States, Canada, and the rest of the world. Maximum of revenue is gained from Specialty Vehicles Segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.